Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Pre-Mkt 05-01 09:28:05 EDT

1.25

+0.01

+0.81%

盘前1.28

+0.03+2.40%

08:47 EDT

High1.28	Low1.22	Vol743.11K
Open1.22	D1 Closing1.24	Amplitude4.83%
Mkt Cap145.33M	Tradable Cap126.00M	Total Shares116.26M
T/O933.79K	T/O Rate0.74%	Tradable Shares100.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":1.25,"timestamp":1777579200000,"preClose":1.24,"halted":0,"volume":743109,"hourTrading":{"tag":"盘前","latestPrice":1.28,"preClose":1.25,"latestTime":"08:47 EDT","volume":55,"amount":70.4200035,"timestamp":1777639651597,"change":0.03,"changeRate":0.024,"amplitude":0.02368},"delay":0,"changeRate":0.008064516129032265,"floatShares":100797117,"shares":116263459,"eps":-1.149999,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"05-01 09:28:05 EDT","open":1.22,"high":1.2799,"low":1.22,"amount":933794.8564995,"amplitude":0.048306,"askPrice":1.34,"askSize":10000,"bidPrice":1.26,"bidSize":288,"shortable":3,"etf":0,"ttmEps":-1.149999,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777642200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.28,"preClose":1.25,"latestTime":"08:47 EDT","volume":55,"amount":70.4200035,"timestamp":1777639651597,"change":0.03,"changeRate":0.024,"amplitude":0.02368},"postHourTrading":{"tag":"盘后","latestPrice":1.27,"preClose":1.25,"latestTime":"19:41 EDT","volume":1662,"amount":2087.67,"timestamp":1777592503764,"change":0.02,"changeRate":0.016,"amplitude":0.032},"volumeRatio":0.7489588176286264,"impliedVol":0.874,"impliedVolPercentile":0.304},"requestUrl":"/m/hq/s/FATE/tweets","defaultTab":"tweets","newsList":[{"id":"2631630119","title":"Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631630119","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631630119?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:00","pubTimestamp":1777554000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284910/24675/en/Fate-Therapeutics-Announces-Data-Presentation-of-FT819-Off-the-Shelf-CAR-T-Cell-Product-Candidate-for-Systemic-Lupus-Erythematosus-SLE-at-the-CCR-East-2026-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","FATE","BK4077","CAR","BK4230","CCR","SLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630822251","title":"Fate Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630822251","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630822251?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:05","pubTimestamp":1777061102,"startTime":"0","endTime":"0","summary":"Fate Therapeutics will hold its annual stockholder meeting in San Diego on June 12, 2026.Stockholders will vote on election of three Class I directors.Agenda includes advisory vote on named executive officer compensation.Meeting will also consider ratification of Ernst & Young as independent auditor for fiscal 2026.Another proposal seeks to increase shares reserved under 2022 Stock Option and Incentive Plan by 7,000,000 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL70bLRq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627156972","title":"Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627156972","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627156972?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:00","pubTimestamp":1776344400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/16/3275450/24675/en/Fate-Therapeutics-Announces-Data-Presentation-of-FT839-Next-Generation-Off-The-Shelf-CAR-T-Cell-Product-Candidate-for-the-Broad-Treatment-of-Hematological-Malignancies-and-Autoimmu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","BK4022","BK4139","BK4230","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626205187","title":"Fate Therapeutics to present at five investor conferences in second quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626205187","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626205187?lang=en_us&edition=fundamental","pubTime":"2026-04-09 21:07","pubTimestamp":1775740064,"startTime":"0","endTime":"0","summary":"Fate Therapeutics management scheduled to participate in 25th Annual Needham Virtual Healthcare Conference on April 14.Company also set for Bank of America Healthcare Conference on May 13 in Las Vegas.Additional appearances planned for H.C. Wainwright BioConnect Investor Conference on May 19 in New York.Fate Therapeutics to attend Jefferies Global Healthcare Conference on June 4 in New York.Goldman Sachs Annual Global Healthcare Conference appearance slated for June 10 in Miami Beach.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL9KR9Mh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","IE00BN0W2W23.USD","BK4585","BK4112","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624468236","title":"Fate Therapeutics grants 7,260 RSUs to newly hired employee under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624468236","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624468236?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:11","pubTimestamp":1775160669,"startTime":"0","endTime":"0","summary":"Fate Therapeutics granted restricted stock units covering 7,260 common shares to one newly hired non-executive employee on April 1, 2026.RSUs vest over four years, with 25% vesting on each anniversary of grant date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3s3zPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BN0W2W23.USD","LU0314104364.USD","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4139","BK4588","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","SG9999014005.SGD","FATE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624768232","title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624768232","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624768232?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:05","pubTimestamp":1775160300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267832/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566017","title":"Fate Therapeutics Grants 50,700 RSU Inducement Awards to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566017?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658380,"startTime":"0","endTime":"0","summary":"Fate Therapeutics said it granted restricted stock units covering 50,700 shares to three newly hired non-executive employees. The awards were made under the company’s Amended and Restated Inducement Equity Plan and vest over four years, with 25% vesting on each anniversary of the March 2, 2026 grant date, subject to continued employment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL4fdR3q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","BK4585","BK4588","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","NDAQ","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569502","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569502","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569502?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:05","pubTimestamp":1772658300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  04, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripoten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249721/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616536575","title":"Bank of America Securities Sticks to Their Hold Rating for Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616536575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616536575?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:56","pubTimestamp":1772618176,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on Fate Therapeutics, with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-hold-rating-for-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-hold-rating-for-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616371248","title":"Fate Therapeutics to Join Leerink Partners 2026 Global Healthcare Conference Fireside Chat and Investor Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2616371248","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616371248?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:06","pubTimestamp":1772571971,"startTime":"0","endTime":"0","summary":"Fate Therapeutics to Join Leerink Partners 2026 Global Healthcare Conference Fireside Chat and Investor Meetings               Fate Therapeutics Inc. will participate in a fireside chat and host inves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL51BxjT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014021.USD","BK4139","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","FATE","SG9999014039.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4585","BK4207","LU2095319765.USD","NDAQ","MNSH","SG9999014005.SGD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616325661","title":"ROC Strengthens Position as Leading Age Estimation Provider in NIST’s Child Online Safety Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2616325661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616325661?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:30","pubTimestamp":1772544600,"startTime":"0","endTime":"0","summary":"ROC’s algorithmic strength secures NIST’s top ranking in age estimation accuracy; ranked #1 globally in Child Online Safety and Mugshot dataset, underscoring ROC’s commitment to developing digital saf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/03/3248366/0/en/ROC-Strengthens-Position-as-Leading-Age-Estimation-Provider-in-NIST-s-Child-Online-Safety-Evaluation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4023","ROC","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616342588","title":"Fate Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342588?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:59","pubTimestamp":1772539181,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryFate Therapeutics Inc FATE.OQ reported a quarterly adjusted loss of 27 cents per share for the quarter ended D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL8N3ZR193:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614040673","title":"Fate Therapeutics reports lower Q4 collaboration revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040673","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040673?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:09","pubTimestamp":1772114954,"startTime":"0","endTime":"0","summary":"Fate Therapeutics reports lower Q4 collaboration revenueOverviewBiopharmaceutical firm's Q4 collaboration revenue fell yr/yrCompany reported Q4 net loss of $32.4 mlnOperating expenses decreased 30% in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614040399","title":"Fate Therapeutics posts FY 2025 net loss of USD 136.3 million, down 26.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040399?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:02","pubTimestamp":1772114541,"startTime":"0","endTime":"0","summary":"Fate Therapeutics posts FY 2025 net loss of USD 136.3 million, down 26.8%               Fate Therapeutics reported Q4 2025 revenue of USD 1.4 million and a net loss of USD 32.4 million, with total ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL2KNGtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","BK4585","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014021.USD","BK4139","BK4112","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","BK4588","SG9999014013.SGD","FATE","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614040590","title":"Fate Therapeutics Inc: Projected Operating Runway Through Year-End 2027, Supported by $205 Mln in Cash, Cash Equivalents, and Investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2614040590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614040590?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114410,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA7T8HHP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614834040","title":"Fate Therapeutics Q4 Basic EPS USD -0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2614834040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614834040?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX807451:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614408390","title":"Fate Therapeutics Q4 Income From Operations USD -34.721 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614408390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614408390?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX807451:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614028936","title":"Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028936","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614028936?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:00","pubTimestamp":1772114400,"startTime":"0","endTime":"0","summary":"Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245685/24675/en/Fate-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1670711040.USD","BK4139","LU1670710588.SGD","BK4213","IE00B42XCP33.USD","LU2360032135.SGD","SG9999015358.SGD","LU1868837300.USD","LU0320765646.SGD","BK4585","LU1221951046.USD","LU2264538146.SGD","LU0175139822.USD","LU2237443978.SGD","BK4008","LU1868836757.USD","LU2237443382.USD","BK4588","SG9999014559.SGD","LU2506952170.USD","SG9999015341.SGD","LU1718418525.SGD","SG9999002224.SGD","BK4533","SGXZ23171101.USD","LU2125154935.USD","LU1032466523.USD","BK4504","LU1868836591.USD","LU1988902786.USD","IE00BLSP4452.SGD","SG9999014575.USD","BK4077","LU1670710661.SGD","LU0106261372.USD","LU0323591593.USD","IE00B3PB1722.GBP","LU0061474960.USD","LU0265550359.USD","IE0031619046.USD","LU0225283273.USD","LU0949170772.SGD","LU0061475181.USD","LU1894683348.USD","LU2237443549.SGD","LU2506951875.HKD","IE00BVYPNV92.GBP","LU0265550946.USD","LU0795875086.SGD","LU0957791311.USD","LU2065731478.USD","LU0096364046.USD","SG9999004303.SGD","BK4559","LU2347655156.SGD","LU1064131342.USD","BK4080","LU1116320901.HKD","LU2237443465.HKD","BK4022","LU0098860793.USD","IE00B66KJ199.SGD","LU0234572021.USD","LU0950375773.USD","LU0823417653.USD","LU1196500208.SGD","LU0553294199.USD","LU2108987350.USD","BK4230","LU0006306889.USD","LU2506952097.USD","LU0661504455.SGD","LU0823417737.USD","BK4187","LU1032955483.USD","BK4231","SG9999002232.USD","LU2506951958.HKD","IE00B7SZL793.SGD","LU1059921491.USD","SG9999014542.SGD","LU0868494617.USD","SG9999011175.SGD","SG9999014567.USD","IE00BDGV0183.EUR","BK4109","LU1116320737.USD","LU0963586101.USD","LU2237957811.SGD","LU2279689827.SGD","BK4581","LU1670711123.USD","LU0795875169.SGD","LU0738911758.USD","LU0266512127.USD","BK4500","LU2237443895.HKD","LU1221951129.SGD","LU1162221912.USD","BK4177","LU1732799900.SGD","FATE","LU1815333072.USD","LU0912757837.SGD","LU2237443622.USD","IE00BLSP4239.USD","LU2463526074.USD","LU1894683264.USD","BK4006","IE00BGHQF631.EUR","IE00B19Z4B17.USD","LU1003077747.HKD","LU0545039389.USD","SG9999003800.SGD","LU1868836914.USD","LU2237957902.USD","BK4610","LU2097829019.USD","IE00BN8TJ469.HKD","LU2133065610.SGD","LU2125154778.USD","LU1732800096.USD","IE00BBT3K403.USD","LU0456854461.SGD","BK4532","IE00BVYPNW00.USD","LU1868837136.USD","LU0289960550.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612445027","title":"Aware Raises the Bar with Industry-Leading Biometric Certifications and Evaluations","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445027","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445027?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:31","pubTimestamp":1771335060,"startTime":"0","endTime":"0","summary":"Third-party evaluations validate fraud-resilient, low-friction identity verification as deepfakes and injection attacks accelerate.BURLINGTON, Mass., Feb.  17, 2026  (GLOBE NEWSWIRE) -- As generative ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239309/0/en/Aware-Raises-the-Bar-with-Industry-Leading-Biometric-Certifications-and-Evaluations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4023","DHS","BK4139","AWRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608800117","title":"Fate Therapeutics Grants Stock Options and RSUs to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2608800117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608800117?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152714,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc. has granted a newly hired non-executive employee non-qualified stock options to purchase 120,000 shares of common stock at an exercise price of $1.19 per share, the company’s closing price on January 30, 2026. Additionally, the employee received restricted stock units  representing 90,000 shares. The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the next three years. The RSUs will vest in equal 25% increments on each anniversary of the grant date over four years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLr02VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","BK4585","FATE","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","BK4112","LU0314104364.USD","SG9999014013.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.053},{"period":"1month","weight":0.0417},{"period":"3month","weight":0.0504},{"period":"6month","weight":-0.0741},{"period":"1year","weight":-0.0234},{"period":"ytd","weight":0.2721}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.020051},{"month":6,"riseRate":0.5,"avgChangeRate":0.003206},{"month":7,"riseRate":0.416667,"avgChangeRate":0.050198},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024603},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}